Background. In 2012, new clinical guidelines were introduced for use of erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD) patients, recommending lower haemoglobin (Hb) target levels and thresholds for ESA initiation. These changes resulted in lower blood levels in these patients. However, there is limited evidence on just when ESA should be initiated and the safety of a low Hb initiation policy. Methods. In this observational inception cohort study, Swedish, nephology-referred, ESA-naïve CKD patients (n ¼ 6348) were enrolled when their Hb dropped below 12.0 g/L, and they were followed for mortality and cardiovascular events. Four different ESA treatments were evaluated applying dynamic marginal structural models: (i) begin ESA immediately, (ii) begin ESA when Hb <11.0 g/dL, (iii) begin ESA when Hb <10.0 g/dL and (iv) never begin ESA in comparison with 'current practice' [the observed (factual) survival of the entire study cohort]. The adjusted 3-year survival following ESA begun over a range of Hb (from <9.0 to 12.0 g/dL) was evaluated, after adjustment for covariates at baseline and during follow-up. Results. Overall, 36% were treated with ESA. Mortality during follow-up was 33.4% of the ESA-treated and 27.9% of the non-treated subjects. The adjusted 3-year survival associated with ESA initiation improved for subjects with initial Hb <9.0 to 11 g/dL and then decreased again for those with Hb above 11.5 g/dL. Initiating ESA at Hb <11.0 g/dL and <10.0 g/dL was associated with improved survival compared with 'current practice' [hazard ratio (HR) 0.83; 95% confidence interval (CI) 0.79-0.89 and 0.90; 95% CI 0.86-0.94, respectively] and did not increase the risk of a cardiovascular event (HR 0.93; 95% CI 0.87-1.00).
I N T R O D U C T I O N
Anaemia is twice as common in patients with chronic kidney disease (CKD) as in the general population, affecting about half of pre-dialysis patients (CKD stage 5) [1] . Anaemia is associated with mortality and cardiovascular complications such as left ventricular hypertrophy and heart failure, both in the general population [2, 3] and in patients with CKD [4, 5] . Treating anaemia in dialysis patients with erythropoiesis-stimulating agents (ESA) reduces the risk for blood transfusion and increases patient-related quality of life [6, 7] . However, randomized controlled trials (RCTs) of ESA therapy studying normalization of haemoglobin (Hb) in CKD patients have failed to demonstrate any beneficial effect on cardiovascular outcomes or death. Instead, they have indicated some potential harmful effects [8] [9] [10] [11] [12] . Furthermore, in some ESA trials including anaemic cancer patients, higher mortality and cancer reoccurrence were observed [13, 14] . On the basis of this evidence, the recommended Hb initiation level for ESA use in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines has been modified from 11 to <10 g/dL, with the statement that it is no longer recommended to maintain Hb values above 11.5 g/dL and with no lower Hb limit at which to initiate ESA treatment [15] . The suggested target level by the European Renal Best Practice group is 10-12 g/dL, and they also suggest not rou- tinely letting Hb fall below 10 g/dL [16] . The US Food and Drug Administration and the European Medicine Agency further recommend that ESA should be used at the lowest possible dose to control anaemia and avoid blood transfusions [17] .
These recommendations have had substantial impact [18] . In the USA, the mean Hb levels and ESA doses in dialysis patients have decreased dramatically; the number of patients with Hb <10 g/dL doubled during 2010-12 [19] , and the number of blood transfusions has considerably increased [20] . Moreover, there is little evidence to support a low Hb initiation policy from the existing trials, as they all addressed high Hb targets (ESA treatment intended to increase Hb >13 g/dL). Furthermore, real-life patients may also differ from those taking part in RCTs. In other areas, carefully designed observational studies have been used to study whether an unselected real-life population benefits from treatments shown to be effective in an RCT [21] . However, traditional observational studies of our study question can be confounded by indication. Indeed, standard statistical methods cannot properly adjust for time-varying patient characteristics (such as Hb or albumin levels), and inverse probability (IP) weighting techniques would be more appropriate [22, 23] .
In this study, we used a large national inception cohort of anaemia in stage 3-5 CKD patients and determined the mortality and cardiovascular risk associated with various clinically relevant ESA initiation regimes. To reduce confounding, we adjusted for an extensive set of patient characteristics, both stationary and time-varying, using IP weighting techniques.
M A T E R I A L S A N D M E T H O D S

Study population
We selected all patients >18 years of age without a previous kidney transplant or dialysis treatment included in the Swedish Renal Registry-Chronic Kidney Disease [24] (SRR-CKD) between 1 July 2005 and 31 December 2011. The study population thus consisted of CKD patients referred to a nephrologist, but not yet on dialysis. Patients were monitored after entering the registry and subsequently enrolled in the present study at the first registered visit, where the Hb level was 12 g/dL and the estimated glomerular filtration rate (eGFR) by the 4-variable Modification of Diet in Renal Disease equation (MDRD) [25] was <60 mL/min/1.73 m 2 . We refer to this visit as the 'study baseline'. The enrolment criteria were chosen to ensure both the presence of anaemia [26] and stage 3-5 CKD, and were similar but not identical to the criteria applied in the three latest RCTs of ESA treatment in CKD [8, 10, 11] . Patients were excluded if they were using ESA at the study baseline, or if they had a prescription for ESA (as per the Swedish Registry of Dispensed Drugs [27] ) within 6 months before the study baseline. We then followed the patients until death or 31 December 2012, whichever came first.
Nearly all nephrology clinics in Sweden (96%) report to the SRR-CKD. According to the general guidelines of the registry, all nephrology-referred patients with an eGFR <30 mL/min/ 1.73 m 2 should be included (with an option to include patients earlier) and followed up until start of renal replacement therapy, when they are transferred to the interlinked dialysis and transplantation registry (SRR). The estimated national coverage is 75-90% of the pre-dialysis nephrology population with stage 4-5 CKD [24] . Results from clinical examinations (height, weight, blood pressure) and laboratory tests are entered into a webbased system along with the current prescription for ESA and other drugs. Many clinics enter all out-patient visits and all laboratory values, but some clinics restrict the number of visits and laboratory tests entered. At entry, patients receive written information about SRR; any patient could choose not to participate in the registry, but few exercised this right. According to Swedish law, written consent is not required because quality control is an inherent element of hospital health care. The study protocol was approved by the regional ethics committee in Stockholm.
Measures
ESA treatment and outcomes. The decision to initiate ESA was made by a treating nephrologist during any out-patient visit. ESA was considered 'initiated as a new ESA use' if treatment with it was begun at an out-patient visit, or if a new prescription for ESA was recorded in the Registry for Dispensed Drugs [27] (for detailed information, see Supplementary data).
ESA treatment regimes were defined a priori to the analyses. The regimes considered can be described as 'initiate ESA at the out-patient visit when the patient's Hb has dropped below a given threshold, and do not initiate ESA when the patient's Hb still exceeds the same given threshold'. The Hb thresholds we chose were to 'initiate ESA immediately' at study baseline for first Hb 12 g/dL, at Hb <11 g/dL, at Hb <10 g/dL and 'never initiate ESA'. In addition to these special cases, we varied the Hb threshold over a range from <9.0 to 12 g/dL.
Furthermore, using the Swedish personal identification number, the cohort was linked to other national registries: the cause of death registry (for date and cause of death) and the National Patient Registry [NPR; for all International Classification of Diseases (ICD) codes and dates of all hospitalizations prior to study inclusion and during follow-up]. The cardiovascular outcome was a composite of the first ICD code for fatal and non-fatal ischaemic stroke, fatal and non-fatal myocardial infarction, venous thromboembolism or pulmonary embolism (see definition in Supplementary data) during followup. Non-cardiovascular death was censored in the analysis for cardiovascular event.
Covariates. All demographic, laboratory and clinical covariates were part of the regular clinical work-up and were used as entered into the SRR-CKD. The primary renal disease was classified by the treating nephrologist. Information on comorbidities (e.g. diabetes, previous cerebrovascular disease or cancer) was obtained from the NPR as identified by ICD codes and recoded into a Charlson Comorbidity Index Score [28, 29] at baseline and updated at each visit during follow-up. During each visit, the local administrator filled in the current medications (vitamin D, anti-hyperlipidaemia treatment, antihypertensive medication and iron use) and clinical information (height, weight, blood pressure, prescribed protein-restricted diet <0.6 g/kg/day). Data for mandatory laboratory covariates were also entered (Hb, calcium, albumin, phosphate, C-reactive protein, creatinine and parathyroid hormone), along with nonmandatory variables (e.g. ferritin, weight and albuminuria). eGFR was calculated from the creatinine level using the MDRD equation. The majority of creatinine assessments (98%) were performed by either the enzymatic method or the corrected Jaffe method (alkaline picrate reaction), both of which are traceable to isotope dilution mass spectrometric standards. Blood Hb levels were measured by accredited methods at any of the local clinical chemistry laboratories. Dates of any subsequent renal replacement therapies (dialysis, renal transplantation) were obtained from the SRR.
Statistical analysis
The primary outcome was all-cause mortality, and the secondary outcome was the first occurrence of a cardiovascular event. To properly adjust for confounding, we carried out an analysis based on IP weighting and dynamic marginal structural models. A brief explanation of the method is provided here, and a detailed account is provided in the Supplementary data. The IP weighting scheme uses an accumulated (across follow-up) propensity score [30, 31] to address confounding by measured baseline and time-varying covariates. To estimate the accumulated propensity score, we used a pooled logistic regression model, adjusted for all measured covariates (see the Supplementary data) as well as missing-ness of any of the laboratory measurements. In our study, we used age, sex and primary renal disease as fixed covariates, whereas all other variables were used as time-varying. The IP-weighted model thus takes into account both fixed and time-varying covariates and is today considered the best available method when studying observational cohort data with time-varying covariates [23] . Also, this type of analysis enables us to compare a far wider range of ESA treatment regimes than can realistically be done in any RCT. Because the aim of this study was to assess mortality associated with ESA initiation in CKD non-dialysis patients, we studied ESA initiation regimes only up until the start of dialysis or transplantation in our analysis. However, follow-up was continued regardless of dialysis initiation, since ESA initiation before start of RRT may affect mortality even after start of RRT. RRT initiation was handled in the statistical model as a timedependent covariate. For information on how censoring was handled, see Supplementary data, pp. 5-6. For information on the handling of missing data, see Supplementary data, Estimation of weights, pp. 7-8.
To estimate the effect of a specific treatment regime, we calculated the IP-weighted Kaplan-Meier curve for those who were observed to comply with that regime. In the absence of unmeasured confounding, the IP-weighted KaplanMeier curve for a given regime illustrates the hypothetical survival that would have been observed had all patients followed this particular regime. A subtle feature of dynamic marginal structural models is that a patient may comply with several regimes at the same time and may also cease to comply with any regime at some point; we give examples of this in the Supplementary data. As a comparison, we calculated the standard (unweighted/crude) Kaplan-Meier curve for all patients in the cohort. This survival curve illustrates the survival of the cohort under 'current treatment practice', which in fact is a mix of all strategies currently used in the study population. To further quantify the differences between treatment regimes, we used an IP-weighted Cox proportion hazards model. In this model, 'current practice' was used as the reference. We tested for differences between regimes using an IP-weighted log-rank test.
The IP-weighted analysis for the main study outcome was first carried out in the whole cohort and thereafter stratified by sex, age, presence of diabetes or previous cancer history. We then repeated all analyses for our secondary outcomes. We further performed several sensitivity analyses. First, we used two different ESA treatment definitions and also complete cases for ESA treatment (see Supplementary data, Tables S6-S9 ). Then, we repeated the analyses using 'initiate ESA at a high dose' and 'initiate ESA at a low dose' for each Hb regime. The weekly ESA dose was converted to epoetin equivalent dose using a conversion factor of 200:1 (darbepoetin alfa and methoxy polyethylene glycol-epoetin beta). We used the highest quartile (epoetin equivalent dose !6000 IU) to define a high dose at initiation (Supplementary data, Table S10 ).
R E S U L T S
The study flow chart is presented in Figure 1 . There were 6348 CKD patients who met the inclusion criteria; 61% were men and the median age was 71.4 years. Baseline characteristics and the characteristics at different times during follow-up of the cohort are presented in Table 1 . In total, 35.5% initiated ESA. The median Hb level at ESA initiation was 10.5 g/dL [interquartile range (IQR) 9.9, 11.4 g/dL]. For those who started ESA, the median ESA (epoetin equivalent dose) at initiation was 4000 U/ week (IQR 3000, 6000) and, during follow-up, the median dose was 4000 U/week (IQR 2500, 6000). Most of the subjects (52.6%) were prescribed darbepoetin alfa. Other formulations including epoetin beta, methoxy polyethylene glycol-epoetin beta, epoetin zeta, epoetin theta and epoetin alfa were prescribed to 21.8, 13.1, 5.3, 4.0 and 3.1% of patients, respectively. The characteristics of the subjects who adhered to the different ESA regimes are presented in Table 2 . The median achieved Hb value was 11.8 g/dL (IQR 11.0, 12.6) for those following the regime 'initiate at <11 g/dL' and 11.5 g/dL (IQR 10.5, 12.4) for those who followed the regime 'initiate at <10 g/dL'. During a median follow-up time of 2.1 years (25-75th percentile 1.2, 3.3), 2067 subjects started renal replacement therapy (57.9% started with haemodialysis, 35.4% started with peritoneal dialysis and 6.7% were kidney transplanted) and 1893 subjects died. Causes of deaths are listed in the Supplementary data, Table S1 . 
Mortality
'initiate at Hb <10 g/dL' (dark blue line) and 'initiate at Hb <11 g/dL' (light blue line). We observe that the survival for the regimes 'current practice', 'initiate ESA immediately' and 'never start' are almost identical. The survival for the regime 'initiate at <10 g/dL' was slightly improved, and the survival for the regime 'initiate at <11 g/dL' was the highest. This observation is supported by the IP-weighted Cox regression analysis (Table 3 ): using 'current practice' as the reference regime, we obtained estimated hazard ratios (HR) 0.90 [95% confidence interval (CI) 0.86-0.94] and HR 0.83 (95% CI 0.79-0.89) for regimes 'initiate at <10 g/dL' and 'initiate at <11 g/dL', respectively. The P-value of the IP-weighted log-rank test was <0.0001. Figure 4 displays the 3-year survival probability, as obtained from the IP-weighted Kaplan-Meier curves, for all Hb thresholds between 9 and 12 g/dL. We observe that the survival probability increases when the Hb level threshold increases from Hb <9 to 11 g/dL and then decreases up to the threshold of 12 g/ dL. However, CIs were wide at both ends due to the low number of patients following these specific regimes. Stratification by sex, age, diabetes and cancer gave similar results to the unstratified analysis (see Supplementary data, Tables S2-S5). The sensitivity analyses, including those on initiating at a high versus low ESA dose, yielded similar results to the main analysis (Supplementary data, Tables S6-S11).
Cardiovascular events
The results for time to first cardiovascular event are displayed in Table 3 . In a total of 1087 (17.1%) subjects, a fatal or non-fatal cardiovascular event occurred during follow-up; 430 of these (19.0%) were ESA-treated and 661 (16.1%) were non-ESA-treated. Fatal or non-fatal strokes occurred in 59 (2.6%) of the ESA-treated subjects during follow-up, whereas 90 (2.2%) among the non-treated had parallel stroke events. The IPweighted Cox proportional hazards analysis for time to a first cardiovascular event showed estimates similar to the main analysis, with lower HRs for 'initiate at <10 g/dL' and 'initiate at <11 g/dL' compared with 'current practice'.
D I S C U S S I O N
Although there is some evidence that treating anaemia with high ESA doses to a goal of high Hb targets may be harmful to the CKD patient, the lower threshold for initiating ESA safely is uncertain. The only placebo-controlled study partially addressing this, the 'Trial to Reduce Cardiovascular Events with Aranesp Therapy' (TREAT) study, used a rescue therapy at Hb below 9 g/dL [10] . In comparison, two other RCTs [Cardiovascular Risk Reduction by Early Anemia Treatment In the 2012 KDIGO guidelines, there is a 'no floor' Hb level for ESA initiation-a regime that has been questioned [16, 32] , especially since two of the RCTs used ESA treatment in the control group and also because in TREAT, about 46% of the controls were given at least one dose of darbepoetin alfa and were given more blood transfusions and more iron [10] . In this analysis of unselected nephrology-referred patients in a nationwide cohort, the results indicate that ESA initiation per se is not associated with increased mortality or cardiovascular events in CKD patients. Nonetheless, our results suggest also that the effect of ESA may depend on when it is initiated in the course of the disease. In particular, our results suggest that it may be optimal to initiate ESA when Hb drops below 11 g/dL, but not earlier. Our results, however, do not favour the use of a 'no floor' Hb initiation level, Presented as mean [standard deviation (SD)] or median (IQR 25-75th percentile distribution) depending on the underlying distribution, or percentage (of non-missing total). eGFR estimated by the 4-variable MDRD equation for standardized creatinine. Protein-restricted diet defined as prescribed diet 0.6 g/kg body weight. To convert g/dL to g/dL divide by 10 (haemoglobin, albumin). To convert mg/dL to mmol/L multiply by 0.25 (total calcium). To convert ng/mL to nmol/L multiply by 0.331 (C-reactive protein) and to convert ng/mL to pmol/L multiply by 2.247 (ferritin); to convert mg/dL to mmol/L multiply by 0.323 (phosphorus). ESA, erythropoietin stimulating agent. Chronic obstructive pulmonary disease To convert g/dL to g/dL divide by 10 (Hb, albumin). To convert mg/dL to mmol/L multiply by 0.25 (total calcium). To convert ng/mL to nmol/L multiply by 0.331 (C-reactive protein) and to convert ng/mL to pmol/L multiply by 2.247 (ferritin); to convert mg/dL to mmol/L multiply by 0.323 (phosphorus). Presented as mean [standard deviation (SD)] or median (IQR 25-75th percentile distribution) depending on the underlying distribution or percentage (of non-missing total). eGFR estimated by the 4-variable MDRD equation for standardized creatinine. Protein-restricted diet defined as prescribed diet 0.6 g/kg body weight.
a Note that patients may comply with several regimes at the same time and also with no pre-specified regime. n ¼ 97 of the patients overlapped between the ESA regimes 'initiate at <10 g/dL', 'initiate at <11 g/dL' and 'initiate ESA immediately'.
b These patients did not follow any predetermined ESA regime but were included in the analyses to the time point when they violated each regime.
as we also observe an increasing mortality risk when initiating ESA below 9.0 g/dL.
There are almost no studies specifically designed to study the effect of ESA initiation. One previous RCT comparing early intervention with low-dose ESA (1000 IU/week) at Hb <11 g/ dL showed stable Hb levels for the treatment group and no significant difference in adverse events compared with a lateinitiation regime [33] . Another observational study saw fewer renal events among patients initiating ESA at 11 g/dL compared with 9 g/dL [34] . In the CREATE study, the control group had a strategy close to our regime of 'initiate at <10 g/dL' and ESA doses similar to ours [11] . Also, in CHOIR, the control group initiated ESA in the Hb range considered in our study, although the ESA doses were slightly higher than ours [8] . The mean achieved Hb after ESA initiation here was close to the Hb values of the control group in both CREATE and CHOIR. The overall mortality and the proportion of patients starting dialysis were much higher in our cohort compared with the prior trials. This reflects the study population, as our cohort represents the general, unselected nephrology-referred population in Sweden, which is both older and has lower eGFR than the patients recruited to the RCTs. In the main analysis, we did not consider ESA dosage. Although high ESA doses have consistently been associated with poorer outcomes, especially among hyporesponsive patients [35, 36] , our main aim with this analysis was to investigate the specific role of ESA initiation timing on mortality and cardiovascular events. In this context, ESA dose is less relevant because the treating nephrologist cannot know how responsive to epoetin the patient will be at the time of initiation of therapy. However, since it is possible that the physicians prescribing initial epoetin treatment estimated ESA responsiveness for the individual patient based on clinical experience, we also performed a sensitivity analysis of the ESA starting dose for each specific regime. The results were similar to the main analyses, leading us to believe that within the relatively narrow starting dose range seen in this study there were no major differences in outcomes for those starting at a high dose compared with those starting at a low dose. However, we did not consider ESA treatment changes later, during the course of therapy, in response to increasing Hb levels or poor responsiveness. It is not possible therefore to draw any conclusions regarding target Hb levels or ESA maintenance doses. An analysis addressing these factors would be possible, but would also fail to answer the specific question of ESA initiation. Instead, in our analysis, the treatment strategy after ESA initiation was left to the treating nephrologist, who would mainly be following current practice in Sweden, which during the time period considered was based on the European Best Practice Guidelines and to some extent KDOQI guidelines, though the KDIGO guidelines were published in 2012 after our study period. The guidelines changed somewhat over time but in broad terms they suggested using a Hb target range of 10-12 g/dL, stopping ESA when Hb increased above 12-13 g/dL and using ESA at the lowest possible dose. In comparison with the results of RCTs, our results indicate that there is no overall increased risk with ESA treatment. Our study, though, focused on whether ESA initiation per se is associated with increased mortality, in contrast to the trials that studied the effects of a low versus high Hb target. Thus, in the RCTs, the incentive to raise the dose in the early nonresponders was high. This is different from in the present observational study without high targets, in that here low weekly ESA doses (almost 50% lower compared with the median doses in the TREAT study) were used, and this achieved Hb levels close to those of the control groups in the prior trials. Another reason for the lower doses in our study compared to the TREAT study FIGURE 3: Survival probability, as a function of time, for CKD patients treated according to the ESA initiation regimes 'current practice', 'initiate ESA immediately', 'never initiate', 'initiate at <11 g/dL' and 'initiate at <10 g/dL'. The survival probabilities are adjusted for both time-fixed and time-dependent variables using IP weighting. is that at the time of the study, patients in the USA generally received much higher ESA doses compared with European patients [37] . Seen in this context, our results are in agreement with those studies that suggest that it is the aim of achieving high Hb targets and the administration of high doses in nonresponders that may be causing the increased risk of adverse events in ESA-treated subjects [38] [39] [40] , and not the ESA treatment per se. Nevertheless, increasing the Hb threshold for ESA initiation even slightly in CKD non-dialysis patients from today's low levels could result in lower overall transfusion rates, because the probability of a blood transfusion increases at Hb levels below 11 g/dL [41] . This is an observational study that included the vast majority of referred CKD non-dialysis patients with incident anaemia in Sweden. We made use of the shift in the guidelines from higher to lower Hb levels for ESA initiation/use during the study period to undertake a wider range of regimes. We further used modern statistical methods to control for confounding by indication and also had access to a rich set of continuously updated information on these variables. Our protocol made it possible to simultaneously investigate several different regimes of ESA initiation, including 'never use'. The use of repeated, continuously updated variables during follow-up and of IP-weighted adjustment made it possible to account not only for changes in the probability of receiving ESA treatment depending on the current medical situation, but also for the decline in Hb over time. Nonetheless, in some instances we did not have access to information from all visits, we lacked information on transferrin saturation, and changes in the ESA treatment regime could also have been made during hospitalization episodes. To consider this, we also performed a sensitivity analysis where we modelled the initiation Hb level between two intervals (Supplementary data, Table S9), with no major deviation from our principal results. Although we had access to a large number of covariates, there is still, as in all observational studies, the possibility that unmeasured confounders influenced the ESA treatment decision and our results. Our results were, however, also consistent when we used other ways to classify ESA treatment (sensitivity analyses), different Hb intervals or analysis of specific subpopulations. Although there was a relatively high proportion of missing non-mandatory variables (ferritin and body mass index), we do not consider this to be a major limitation because these variables were in many instances also missing for the treating physician and thus possibly unrelated to the nephrologist's treatment decision. Further analyses are needed with the objective of studying the role of the ESA dose and the treatment response.
In conclusion, this observational study investigating treatment regimes for ESA initiation suggests that initiating ESA when Hb drops below 11 g/dL is not associated with increased mortality or cardiovascular events in CKD non-dialysis patients who are otherwise treated according to current guidelines. Instead, ESA initiation when the Hb first drops to <10-11 g/dL may be associated with improved survival. 'Initiate ESA immediately' corresponds to initiation of ESA at baseline, which in this case was at first visit where the Hb level declined below 12.0 g/dL. 'Never initiate' corresponds to a regime where ESA is never initiated. 'Initiate at <11 g/dL' corresponds to a regime where ESA is never initiated at Hb levels above 11 g/dL but always is initiated below 11 g/dL. 'Initiate at <10 g/dL' corresponds to a regime where ESA is never initiated at Hb levels above 10 g/dL but always initiated below 10 g/dL. Reference is 'current practice', which corresponds with the observed (factual) survival of the cohort.
FIGURE 4: Three-year survival probability for CKD patients, for all Hb thresholds between 9.0 and 12 g/dL. The survival probabilities are adjusted for both time-fixed and time-dependent variables using IP weighting. The dotted lines depict the 95% CIs.
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